New drug MK-8294 tested in patients with advanced cancers

NCT ID NCT07030712

Recruiting now Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen Oct 01, 2025 · Last updated May 13, 2026 · Updated 22 times

Summary

This early-stage study tests a new targeted drug called MK-8294 in about 67 people with advanced solid tumors that have spread. The main goal is to check the drug's safety and find the highest dose people can tolerate. Researchers will also watch for any tumor shrinkage, but this is not a cure and ongoing treatment may be needed.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Nederlands Kanker Instituut - Antoni van Leeuwenhoek - NKI-AVL ( Site 0300)
RECRUITING

Amsterdam, North Holland, 1066 CX, Netherlands

Contact Phone: •••-•••-••••
Northwestern University ( Site 0101)
RECRUITING

Chicago, Illinois, 60611, United States

Contact Phone: •••-•••-••••
Radboudumc ( Site 0301)
RECRUITING

Nijmegen, Gelderland, 6525 GA, Netherlands

Contact Phone: •••-•••-••••
Rambam Health Care Campus ( Site 0201)
RECRUITING

Haifa, 3109601, Israel

Contact Phone: •••-•••-••••
Sheba Medical Center ( Site 0200)
RECRUITING

Ramat Gan, 5265601, Israel

Contact Phone: •••-•••-••••

Conditions

Explore the condition pages connected to this study.

METASTATIC NEOPLASM